KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue (2016 - 2025)

Historic Revenue for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $190.2 million.

  • Neogenomics' Revenue rose 1056.4% to $190.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $727.3 million, marking a year-over-year increase of 1010.74%. This contributed to the annual value of $727.3 million for FY2025, which is 1010.74% up from last year.
  • As of Q4 2025, Neogenomics' Revenue stood at $190.2 million, which was up 1056.4% from $187.8 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Revenue registered a high of $190.2 million during Q4 2025, and its lowest value of $115.5 million during Q1 2021.
  • For the 5-year period, Neogenomics' Revenue averaged around $148.7 million, with its median value being $149.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Neogenomics' Revenue was 3994.96% (2021), while the steepest drop was 327.16% (2021).
  • Over the past 5 years, Neogenomics' Revenue (Quarter) stood at $125.7 million in 2021, then rose by 10.32% to $138.7 million in 2022, then grew by 12.15% to $155.6 million in 2023, then grew by 10.57% to $172.0 million in 2024, then increased by 10.56% to $190.2 million in 2025.
  • Its Revenue was $190.2 million in Q4 2025, compared to $187.8 million in Q3 2025 and $181.3 million in Q2 2025.